Gland Pharma Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Gland Pharma Ltd filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Gland Pharma reported Q1 FY27 consolidated revenue of INR18,003 million, up 20% year-on-year, with adjusted EBITDA margin of 28% and profit after tax of INR3,170 million, up 47% year-on-year. Growth was driven by the CDMO and B2B segments, recent product launches, and improved capacity utilization, while the company announced new strategic manufacturing agreements including a large sterile injectables supply deal, a Neuland Laboratories API collaboration, and a China-based liposomal product in-licensing deal. Management also discussed capital expenditure plans, Cenexi's European operations, and provided commentary on growth expectations for the CDMO business over the coming years.
Numbers mentioned
Revenue: INR18,003 million (Q1 FY27)
p. 3
“For the first quarter of FY27, we reported revenues of INR18,003 million, representing a growth of 20% year-on-year.”
Srinivas Sadu, page 3 of the filed PDF · View the filing
Adjusted EBITDA: INR5,102 million (Q1 FY27)
p. 3
“Adjusted EBITDA for this quarter stood at INR5,102 million with margins of 28%, while profit after tax was INR3,170 million, reflecting a healthy growth of 47% year-on-year with PAT margin of 18%.”
Srinivas Sadu, page 3 of the filed PDF · View the filing
CDMO segment revenue: INR8,915 million (Q1 FY27)
p. 4
“Revenue from the CDMO segment stood at INR 8,915 million, which grew by 20% year-on-year and contributed 50% of total revenues during the quarter.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
B2B business revenue: INR9,088 million (Q1 FY27)
p. 4
“Our B2B business revenue stood at INR9,088 million, contributing 50% of total revenues and recorded healthy growth of 19% year-on-year.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
US revenue: INR9,810 million (Q1 FY27)
p. 4
“Revenues for the quarter stood at INR9,810 million, reflecting a growth of 32% year-on-year.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
Europe and other regulatory markets revenue: INR4,488 million (Q1 FY27)
p. 4
“In Europe and other regulatory markets, revenues for the quarter stood at INR4,488 million, reflecting a growth of 11% year-on-year.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
Rest of world revenue: INR3,039 million (Q1 FY27)
p. 4
“In the rest of the world markets, revenues for the quarter stood at INR3,039 million, broadly in line with the corresponding period last year.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
India revenue: INR666 million (Q1 FY27)
p. 5
“In India, revenues for the quarter stood at INR666 million.”
Srinivas Sadu, page 5 of the filed PDF · View the filing
R&D expenditure: INR772 million (Q1 FY27)
p. 6
“During Q1 FY27, we spent INR772 million on R&D, representing around 4% of consolidated revenue.”
Srinivas Sadu, page 6 of the filed PDF · View the filing
Cenexi revenue: EUR48 million (Q1 FY27)
p. 6
“Cenexi's revenue stood at EUR48 million with an EBITDA of EUR2 million.”
Srinivas Sadu, page 6 of the filed PDF · View the filing
Gross margin: 65% (Q1 FY27)
p. 7
“Overall gross margin for the quarter stood at 65%, reflecting the benefits of a favorable product mix, increasing contribution from CDMO projects, improved operational efficiencies and procurement initiatives.”
Ravi Mitra, page 7 of the filed PDF · View the filing
Reported EBITDA margin: 27% (Q1 FY27)
p. 8
“at 27%, higher as compared to 24% in corresponding quarter of previous year.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Cash and cash equivalents: INR35,466 million (as of June 30, 2026)
p. 8
“As of June 30, 2026, total cash and cash equivalents at the group level stood at INR35,466 million.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Net cash position: INR32,939 million (Q1 FY27)
p. 8
“we are a net cash surplus company with a net cash position of INR32,939 million.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Cash flow from operations: INR3,183 million (Q1 FY27)
p. 8
“Cash flow from operations during the quarter remained healthy at INR3,183 million, reflecting strong operating performance and disciplined working capital management.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Capital expenditure: INR1,132 million (Q1 FY27)
p. 8
“Capital expenditure during the quarter amounted to INR1,132 million, primarily towards capacity expansion projects, capability enhancement initiatives, infrastructure additions and investments supporting future growth opportunities across our CDMO and fill/finish platforms.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Effective tax rate: approximately 27% (Q1 FY27)
p. 8
“The effective tax rate for the quarter stood at approximately 27%.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Base business growth (ex-Cenexi): 24% (Q1 FY27)
p. 14
“So the base business has grown by 24%.”
Srinivas Sadu, page 14 of the filed PDF · View the filing
Profit share: about 9% (Q1 FY27)
p. 18
“Profit share is about 9%.”
Srinivas Sadu, page 18 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
New manufacturing and supply agreement revenue potential — USD90 million to USD100 million · once all products are commercialized
stated firmly by Srinivas Sadu
p. 5
“Once all products are commercialized, revenue potential is expected to be approximately USD90 million to USD100 million.”
Srinivas Sadu, page 5 of the filed PDF · View the filing
Revenue commencement from new manufacturing agreement — calendar year 2029
stated firmly by Srinivas Sadu
p. 5
“Technology transfer activities are planned for completion within 2 years with revenues expected to commence from calendar year 2029.”
Srinivas Sadu, page 5 of the filed PDF · View the filing
China liposomal product revenue contribution — FY30
stated firmly by Srinivas Sadu
p. 6
“we expect commercial opportunities and meaningful revenue contribution to start from FY30, creating another important long-term growth driver for the company.”
Srinivas Sadu, page 6 of the filed PDF · View the filing
New ampoule line capacity — approximately 30 million ampoules of annual capacity · early 2027
stated firmly by Srinivas Sadu
p. 6
“This new line is expected to enter production in early 2027 and will add approximately 30 million ampoules of annual capacity for enhancing efficiency, competitiveness and growth potential for the site.”
Srinivas Sadu, page 6 of the filed PDF · View the filing
CDMO business CAGR — around 20% growth · next 4 years
stated conditionally by Srinivas Sadu
p. 11
“But as of now, with this new contract in place, we are looking at 20% -- around 20% growth next 4 years.”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Current year constant currency growth — 15% · FY27
stated conditionally by Srinivas Sadu
p. 11
“While the current year, we still -- with the constant currency, we're still estimating -- we're not estimating, but probably 15% is clearly achievable.”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Growth upside from bag line approval — exceed 15% growth · this year
stated conditionally by Srinivas Sadu
p. 11
“If it's approved by August, September, then probably we'll exceed the 15% growth for this year.”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Consol CDMO share of revenue — 30% near term · near term
stated as an aspiration by Srinivas Sadu
p. 11
“The target is to reach as a consol basis, in a nearby near term, we're looking at 30% near term as a consol basis.”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Consol EBITDA margin target — 35% EBITDA · next 3, 4 years
stated as an aspiration by Srinivas Sadu
p. 12
“We wanted to be a profitable company, hitting those 35% EBITDA.”
Srinivas Sadu, page 12 of the filed PDF · View the filing
Cenexi EBITDA margin — double-digit EBITDA · by the end of the year
stated as an aspiration by Srinivas Sadu
p. 13
“So by the end of the year, we want to get into double-digit EBITDA.”
Srinivas Sadu, page 13 of the filed PDF · View the filing
NDDS project timeline — '28 tech transfer, commercialize '29
stated firmly by Srinivas Sadu
p. 18
“'28, sorry, '28 and commercialize '29.”
Srinivas Sadu, page 18 of the filed PDF · View the filing
Full year capex — about INR550 crores · this year
stated firmly by Ravi Mitra
p. 10
“And to answer your question, Saion, so this year, we are going to spend about INR550 crores capex.”
Ravi Mitra, page 10 of the filed PDF · View the filing
Isolator line capex — about INR165 crores
stated firmly by Srinivas Sadu
p. 10
“So , I would say for one immediate capex is going to about INR165 crores.”
Srinivas Sadu, page 10 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said manufacturing will happen at Indian sites for a specialty pharma global company with a mix of generics and specialty products, with revenue ramping from 2029 to 2030.
Answered by Ravi Mitra
Asked by Saion Mukherjee: Details of the new strategic manufacturing agreement - customer type, manufacturing location, and revenue ramp-up timeline to USD90-100 million.
p. 10
“And the revenues will ramp up from '29 because the filings will start happening from next year.”
Ravi Mitra, page 10 of the filed PDF · View the filing
Management reiterated growth targets, noting current year constant currency growth of about 15% with potential upside, and around 20% CAGR over the next 4 years.
Answered by Srinivas Sadu
Asked by Vivek Gautam: Sustainability of Cenexi turnaround and overall growth opportunity size and differentiation.
p. 11
“But I think next 4 years, we're looking at 20%-odd, but we'll get a clear clarity next quarter”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Management confirmed Q2 would be better than the prior year given delayed quality releases from the heat wave.
Answered by Srinivas Sadu
Asked by Neha M.: Whether Cenexi's Q2 will be less seasonally weak given shipments delayed by the heat wave in Q1.
p. 12
“It really -- I would say it will be better than last year, for sure.”
Srinivas Sadu, page 12 of the filed PDF · View the filing
Management said the new line is on track, with exhibit batches being taken for customers and limited near-term revenue contribution expected.
Answered by Srinivas Sadu
Asked by Ashish: Update on GLP-1 business scale-up and capacity ramp.
p. 12
“So from capacity, the new line is on track. We are taking some exhibit batches from some of the customers whom we have signed up in the last few quarters.”
Srinivas Sadu, page 12 of the filed PDF · View the filing
Management said profitability remained on the same 4% EBITDA trend as before, targeting double-digit EBITDA by year end.
Answered by Srinivas Sadu
Asked by Chintan Sheth: Clarification on Cenexi EBITDA margin trend given the heat wave impact.
p. 13
“No. The profitability is in the same trend like what we said is 4% EBITDA.”
Srinivas Sadu, page 13 of the filed PDF · View the filing
Management stated the base business grew 24% with the US at 32%.
Answered by Srinivas Sadu
Asked by Karan Vora: Base business growth ex-Cenexi in the US and ROW markets.
p. 14
“So the base business has grown by 24%.”
Srinivas Sadu, page 14 of the filed PDF · View the filing
Management confirmed 15% constant currency growth, explaining that FX is calculated based on the date of product dispatch.
Answered by Ravi Mitra
Asked by Rahul Jeewani: Constant currency growth for the quarter at the consolidated level.
p. 17
“So it's a basis of when the products are dispatched. It's not uniformly across every.”
Ravi Mitra, page 17 of the filed PDF · View the filing
Management cited the opportunity from big pharma companies with expensive manufacturing bases looking to shift production, leveraging Gland's operational efficiency and quality track record.
Answered by Srinivas Sadu
Asked by Alankar Garude: Top factors driving CDMO segment growth over recent years.
p. 18
“That opens up a door for us where we have better operational leverage and better history of quality and then at scale, we can do.”
Srinivas Sadu, page 18 of the filed PDF · View the filing
Risks flagged
Supply disruptions in Saudi Arabia impacted rest-of-world revenue
p. 4
“While demand across several key markets remain healthy, revenues in the quarter were impacted by supply disruptions in Saudi Arabia, one of our important markets.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
Delay in NUPCO tender award
p. 4
“The award of NUPCO tenders has been delayed, and we expect the results to be announced shortly.”
Srinivas Sadu, page 4 of the filed PDF · View the filing
Summer heat wave in Europe disrupted Cenexi operations
p. 6
“Despite the disruption of activities caused by the summer heat wave in Europe, the Fontenay facility delivered a good performance, benefiting from the production ramp-up of our new ampoule line and higher operational efficiency.”
Srinivas Sadu, page 6 of the filed PDF · View the filing
Forex loss impacted profit after tax compared to prior quarter
p. 8
“However, as compared to Q4 FY26, the decline in PAT is largely attributable to forex loss in this quarter vis-a-vis forex gain in the previous quarter.”
Ravi Mitra, page 8 of the filed PDF · View the filing
Capacity constraints on bag line and ophthalmic products pending FDA approval
p. 11
“But we're also looking at a couple of lines like the bag line and ophthalmic products we have tight capacity constraints.”
Srinivas Sadu, page 11 of the filed PDF · View the filing
Limited visibility on GLP-1 front-end approval status for customers' products
p. 13
“So it's very difficult to assume the numbers for them.”
Srinivas Sadu, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.